Arch Oncology is an immuno-oncology company focused on the discovery and development of next-generation anti-CD47 antibody therapies to improve treatment options for patients living with cancer.

For more information, visit Arch Oncology or follow their updates on:



  • $155m

Arch Oncology Articles

Cortex Expands with Re-invention of Historic 4340 Duncan Building